Chest Medicine | Page 36 of 170 | Links Medicus Content Curation & Alerts in Medicine

Another study suggests a lower risk of hospitalization and death from infection with SARS-CoV-2 Omicron variant vs. Delta.

18 Feb, 2022 | 10:01h | UTC

Estimates of SARS-CoV-2 Omicron Variant Severity in Ontario, Canada – JAMA

WHO Interim Guidance: Contact tracing and quarantine in the context of the Omicron SARS-CoV-2 variant.

18 Feb, 2022 | 09:59h | UTC

Contact tracing and quarantine in the context of the Omicron SARS-CoV-2 variant: interim guidance – World Health Organization

Commentary on Twitter (thread – click for more)

#COVID19 quarantine period may be shortened for contacts who test negative on a PCR or antigen based rapid diagnostic test. Quarantine can be shortened, for example to seven days, if the contact shows no symptoms & presents a negative test https://t.co/ERF0HDcJOU https://t.co/TsbcHw86B7

— World Health Organization (WHO) (@WHO) February 17, 2022

Cohort study: Protection against SARS-CoV-2 after Covid-19 vaccination lasts longer in patients with previous infection.

17 Feb, 2022 | 10:11h | UTC

Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection – New England Journal of Medicine

RCT: Oral Nirmatrelvir for high-risk adults with Covid-19 reduces the risk of hospitalization by 89%.

17 Feb, 2022 | 10:14h | UTC

Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 – New England Journal of Medicine

Audio Interview: A New Antiviral against Covid-19 – new England Journal of Medicine

[Press release – not published yet] Pfizer’s Covid pill remains 89% effective for reducing the risk of hospitalization or death in final analysis.

[Press release – not published yet] RCT: Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study.

Statement on potential drug-drug interactions between Ritonavir-boosted Nirmatrelvir (Paxlovid) and concomitant medications; antiarrhythmics, oral anticoagulants, immunosuppressants, anticonvulsants, antineoplastics, and neuropsychiatric drugs are among the drugs of concern.

Commentary on Twitter

The Paxlovid pill (Nirmatrelvir) randomized, placebo-controlled trial published @NEJM:
89% efficacy vs Covid hospitalizations or deaths, and quick reduction of viral load.
The active pills had less serious adverse events or discontinuations than placebohttps://t.co/HBMRZt4wBo pic.twitter.com/LDQv41O56c

— Eric Topol (@EricTopol) February 16, 2022

SIMEU position paper on non-invasive respiratory support in COVID-19 pneumonia.

17 Feb, 2022 | 10:01h | UTC

SIMEU position paper on non-invasive respiratory support in COVID-19 pneumonia – Internal and Emergency Medicine

RCT: CPAP improved outcomes in patients with acute hypoxemic respiratory failure due to COVID-19, but high-flow nasal oxygen was not better than conventional oxygen therapy.

RCT: In patients with severe Covid-19, high-flow oxygen therapy reduced the likelihood of invasive mechanical ventilation and decreased the time to clinical recovery compared to conventional oxygen therapy.

Non-invasive respiratory support in the management of acute COVID-19 pneumonia: considerations for clinical practice and priorities for research – “The two randomized controlled trials indicate superiority of non-invasive ventilation over high-flow nasal oxygen in reducing the need for intubation”.

Prone positioning during venovenous extracorporeal membrane oxygenation for acute respiratory distress syndrome: a pooled individual patient data analysis.

17 Feb, 2022 | 08:19h | UTC

Prone positioning during venovenous extracorporeal membrane oxygenation for acute respiratory distress syndrome: a pooled individual patient data analysis – Critical Care

Veno-venous extracorporeal membrane oxygenation (vv-ECMO) for severe respiratory failure in adult cancer patients: a retrospective multicenter analysis.

16 Feb, 2022 | 08:30h | UTC

Veno-venous extracorporeal membrane oxygenation (vv-ECMO) for severe respiratory failure in adult cancer patients: a retrospective multicenter analysis – Journal of Intensive Care

Commentary on Twitter

VV #ECMO in adults with cancer developing severe respiratory failure: survival remains poor, no significant advantage, carefully select! Low PLT, elevated lactate, disease status: adverse prognostic factors to be considered as deciding to provide #ECLS.
🖇️ https://t.co/igatEJH3VS pic.twitter.com/vl7UQKauB0

— Intensive Care Medicine (@yourICM) February 12, 2022

Diagnosis of deep vein thrombosis with D-dimer adjusted to clinical probability: prospective diagnostic management study.

16 Feb, 2022 | 08:39h | UTC

Diagnosis of deep vein thrombosis with D-dimer adjusted to clinical probability: prospective diagnostic management study – The BMJ

Why don’t most people with COVID need to test for another 30 days, even if they’re re-exposed?

15 Feb, 2022 | 10:14h | UTC

Why don’t most people with COVID need to test for another 30 days, even if they’re re-exposed? – The Conversation

Essay: Tuberculosis in times of COVID-19.

15 Feb, 2022 | 10:16h | UTC

Tuberculosis in times of COVID-19 – Journal of Epidemiology & Community Health

Covid-19’s Devastating Effect on Tuberculosis Care — A Path to Recovery.

Global tuberculosis progress reversed by COVID-19 pandemic.

WHO Report: Tuberculosis deaths rise for the first time in more than a decade due to the COVID-19 pandemic.

How COVID is derailing the fight against HIV, TB and malaria.

How COVID hurt the fight against other dangerous diseases

World TB Day | Report: COVID-19 Eliminates Twelve Years of Progress Against Tuberculosis

WHO: Benefits of continuing to provide life-saving HIV services outweigh the risk of COVID-19 transmission by 100 to 1

Tuberculosis and Covid-19: Fighting a deadly syndemic

Potential impact of the COVID-19 pandemic on HIV, tuberculosis, and malaria in low-income and middle-income countries: a modelling study

Scientists deliberately gave people COVID — here’s what they learnt.

15 Feb, 2022 | 10:06h | UTC

Scientists deliberately gave people COVID — here’s what they learnt – Nature

Original Study: [Preprint] Results from the first Covid-19 human challenge study (deliberately infecting individuals in a controlled environment).

Perspective | SARS-CoV-2 human challenge studies — establishing the model during an evolving pandemic.

World’s first coronavirus “Human Challenge” study receives ethics approval in the UK (several texts on the subject)

Are SARS-CoV-2 Human Challenge Trials Ethical? – “A clinical trial is underway in the UK in which young, healthy participants are exposed deliberately to SARS-CoV-2 to assess the viral inoculum needed to produce an infection and to test vaccine efficacy”.

Meta-analysis of randomized clinical trials: vaccines to prevent COVID-19.

15 Feb, 2022 | 10:04h | UTC

Vaccines to prevent COVID-19: A living systematic review with Trial Sequential Analysis and network meta-analysis of randomized clinical trials – PLOS One

Systematic Review: Efficacy of antiviral therapies for COVID-19.

15 Feb, 2022 | 10:02h | UTC

Efficacy of antiviral therapies for COVID-19: a systematic review of randomized controlled trials – BMC Infectious Diseases

Covid-19: Fourth vaccine doses—who needs them and why?

15 Feb, 2022 | 09:59h | UTC

Covid-19: Fourth vaccine doses—who needs them and why? – The BMJ

Data Review: How many people die from air pollution?

15 Feb, 2022 | 08:37h | UTC

Data Review: How many people die from air pollution? – Our World in Data

New WHO Global Air Quality Guidelines aim to save millions of lives from air pollution.

Short-term exposure to ambient air pollution is associated with increased risk of myocardial infarction mortality

1.8 million excess deaths attributable to urban air pollution in 2019, modelling study suggests.

Internalising health-economic impacts of air pollution into climate policy: a global modelling study – The Lancet Planetary Health

Air Pollution Associated with New Causes of Hospital Admissions

Ambient Particulate Air Pollution and Daily Mortality in 652 Cities

Air Pollution and Estimated Life Expectancy Loss

Conflicting reports raise questions about whether any monoclonals work against Omicron’s sister variant.

13 Feb, 2022 | 22:49h | UTC

Conflicting reports raise questions about whether any monoclonals work against Omicron’s sister variant – STAT

FDA halts use of antibody drugs that don’t work vs. Omicron.

Lab study shows new antiviral pills maintain efficacy against Omicron, but antibody drugs are substantially less effective.

ERS statement on Long COVID-19 follow-up.

13 Feb, 2022 | 22:48h | UTC

European Respiratory Society Statement on Long COVID-19 Follow-Up – European Respiratory Review

RCT: In patients with cardiogenic shock receiving VA-ECMO, moderate hypothermia did not significantly reduce 30-day mortality. 42% of patients in the moderate hypothermia group died vs. 51% in the normothermia group (adjusted odds ratio, 0.71 [95% CI, 0.45 to 1.13], P = .15).

13 Feb, 2022 | 22:11h | UTC

Effect of Moderate Hypothermia vs Normothermia on 30-Day Mortality in Patients With Cardiogenic Shock Receiving Venoarterial Extracorporeal Membrane Oxygenation: A Randomized Clinical Trial – JAMA (link to abstract – $ for full-text)

Commentary: Hypothermia vs. Normothermia for Cardiogenic Shock Patients on VA-ECMO – American College of Cardiology

Commentary on Twitter

In this RCT, for patients with cardiogenic shock receiving venoarterial ECMO, moderate hypothermia for 24 hours compared with normothermia did not significantly decrease 30-day mortality. https://t.co/0LKYJ1bNB3 pic.twitter.com/KmXPAlvqh9

— JAMA (@JAMA_current) February 2, 2022